Encorafenib (BRAFTOVI™), in combination with binimetinib (MEKTOVI®) and cetuximab has been designed to treat patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).
BRAFV600E-mutant mCRC will be an important treatment option to the cancer patients in critical need.
The results were made from the safety lead-in of the ongoing randomised Phase 3 BEACON CRC trial showed that, at the time of analysis, the Overall Survival (OS) data were fully mature through 12.6 months and that the median OS had not yet been reached.
The one-year overall survival rate for this cohort was 62 per cent.
Median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95 per cent CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines of therapy.
Confirmed Overall Response Rate (ORR) was 48 per cent and among the 17 patients who received only one prior line of therapy the ORR was 62 per cent.
The triplet combination was generally well-tolerated with no unexpected toxicities.
The most common grade 3 or 4 adverse events seen in at least 10 per cent of patients were fatigue (13%), anemia (10%), increased blood creatine kinase (10%) and increased aspartate aminotransferase (10%).